160 related articles for article (PubMed ID: 26925628)
41. Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.
Zincircioglu SB; Kaplan MA; Isikdogan A; Cil T; Karadayi B; Dirier A; Kucukoner M; Inal A; Yildiz I; Aggil F; Donmez O; Urakci Z; Pekkolay Z; Firat U
J BUON; 2012; 17(1):124-7. PubMed ID: 22517705
[TBL] [Abstract][Full Text] [Related]
42. Molecular dissection of the valproic acid effects on glioma cells.
Hoja S; Schulze M; Rehli M; Proescholdt M; Herold-Mende C; Hau P; Riemenschneider MJ
Oncotarget; 2016 Sep; 7(39):62989-63002. PubMed ID: 27556305
[TBL] [Abstract][Full Text] [Related]
43. The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients.
Li C; Chen H; Tan Q; Xie C; Zhan W; Sharma A; Sharma HS; Zhang Z
Prog Brain Res; 2020; 258():369-379. PubMed ID: 33223038
[TBL] [Abstract][Full Text] [Related]
44. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
45. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
46. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
47. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
48. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
49. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
Tomuleasa C; Soritau O; Kacso G; Fischer-Fodor E; Cocis A; Ioani H; Timis T; Petrescu M; Cernea D; Virag P; Irimie A; Florian IS
J BUON; 2010; 15(4):758-62. PubMed ID: 21229642
[TBL] [Abstract][Full Text] [Related]
50. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Mendez JS; Govindan A; Leong J; Gao F; Huang J; Campian JL
J Neurooncol; 2016 Apr; 127(2):329-35. PubMed ID: 26725885
[TBL] [Abstract][Full Text] [Related]
51. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Galanis E; Anderson SK; Miller CR; Sarkaria JN; Jaeckle K; Buckner JC; Ligon KL; Ballman KV; Moore DF; Nebozhyn M; Loboda A; Schiff D; Ahluwalia MS; Lee EQ; Gerstner ER; Lesser GJ; Prados M; Grossman SA; Cerhan J; Giannini C; Wen PY;
Neuro Oncol; 2018 Mar; 20(4):546-556. PubMed ID: 29016887
[TBL] [Abstract][Full Text] [Related]
52. SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Mellai M; Cattaneo M; Storaci AM; Annovazzi L; Cassoni P; Melcarne A; De Blasio P; Schiffer D; Biunno I
Oncotarget; 2015 May; 6(14):12452-67. PubMed ID: 25948789
[TBL] [Abstract][Full Text] [Related]
53. Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Kresbach C; Bronsema A; Guerreiro H; Rutkowski S; Schüller U; Winkler B
Childs Nerv Syst; 2022 Feb; 38(2):479-483. PubMed ID: 34309720
[TBL] [Abstract][Full Text] [Related]
54. A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
Raj S; Pandit PN; Kishor K
Gulf J Oncolog; 2016 Jan; 1(20):6-11. PubMed ID: 27050173
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
[TBL] [Abstract][Full Text] [Related]
56. Experimental and clinical studies on radiation and curcumin in human glioma.
Sminia P; van den Berg J; van Kootwijk A; Hageman E; Slotman BJ; Verbakel WFAR
J Cancer Res Clin Oncol; 2021 Feb; 147(2):403-409. PubMed ID: 33118056
[TBL] [Abstract][Full Text] [Related]
57. Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Kerschbaumer J; Freyschlag CF; Bauer R; Obwegeser AA; Schubert GA; Thomé C; Seiz M
Anticancer Res; 2012 Dec; 32(12):5515-9. PubMed ID: 23225460
[TBL] [Abstract][Full Text] [Related]
58. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Friedman GK; Spiller SE; Harrison DK; Fiveash JB; Reddy AT
J Pediatr Hematol Oncol; 2013 Apr; 35(3):e123-6. PubMed ID: 23425999
[TBL] [Abstract][Full Text] [Related]
59. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.
Choi J; Kim G; Cho SB; Im HJ
J Nanobiotechnology; 2020 Sep; 18(1):122. PubMed ID: 32883290
[TBL] [Abstract][Full Text] [Related]
60. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
